News Update ARIAD’s AP26113 Receives FD

News Update ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation for ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib http://ow.ly/2OxK3U

Advertisements